Accéder au contenu
Merck

1365000

USP

Levothyroxine

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

L-Thyroxine, 3,3′,5,5″-Tetraiodo-L-thyronine, 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine, T4

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

A propos de cet article

Formule linéaire :
HOC6H2(I)2OC6H2(I)2CH2CH(NH2)CO2H
Numéro CAS:
51-48-9
Poids moléculaire :
776.87
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329750052
MDL number:
MFCD00002595
Beilstein/REAXYS Number:
2228515

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Levothyroxine, United States Pharmacopeia (USP) Reference Standard

InChI key

XUIIKFGFIJCVMT-LBPRGKRZSA-N

SMILES string

N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O

InChI

1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1

grade

pharmaceutical primary standard

API family

levothyroxine

manufacturer/tradename

USP

mp

223 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... THRA(7067), THRB(7068)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Levothyroxine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Levothyroxine Sodium
  • Levothyroxine Sodium Tablets
  • Levothyroxine Sodium Oral Powder
  • Liothyronine Sodium
  • Thyroid
  • Thyroid Tablets
  • Liothyronine Sodium Tablets

Biochem/physiol Actions

L-Thyroxine (T4) and triiodo-L-thyronine (T3) are iodine-containing hormones produced from thyroglobulin in the thyroid follicular cells. The stimulation of metabolic rate and regulation of growth and development by these hormones appear to be due to their effects on DNA transcription and, thus, protein synthesis.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H372

Hazard Classifications

STOT RE 1

target_organs

Thyroid,Cardio-vascular system,Kidney

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Levothyroxine Sodium Tablets
United States Pharmacopeia, 39(1), 3418-3418 (2023)
Levothyroxine Sodium
United States Pharmacopeia, 45(2) (2020)
B Velkeniers et al.
Human reproduction update, 19(3), 251-258 (2013-01-19)
BACKGROUND Previous meta-analyses of observational data indicate that pregnant women with subclinical hypothyroidism have an increased risk of adverse pregnancy outcome. Potential benefits of levothyroxine (LT4) supplementation remain unclear, and no systematic review or meta-analysis of trial findings is available
Michaela Granfors et al.
Obstetrics and gynecology, 124(1), 10-15 (2014-06-06)
To evaluate the efficacy of a targeted thyroid testing approach during pregnancy in clinical practice. This is a retrospective cohort study performed within Uppsala County, Sweden. Data were derived from the population-based Uppsala Biobank of Pregnant Women, in which blood
Peter K Quashie et al.
Journal of virology, 89(6), 3163-3175 (2015-01-02)
Dolutegravir (DTG) is the latest antiretroviral (ARV) approved for the treatment of human immunodeficiency virus (HIV) infection. The G118R substitution, previously identified with MK-2048 and raltegravir, may represent the initial substitution in a dolutegravir resistance pathway. We have found that
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique